cmc considerations for car t cell product development
Published 3 years ago • 11K plays • Length 29:42Download video MP4
Download video MP3
Similar videos
-
30:29
cmc considerations for oncolytic viral product development
-
46:52
preclinical considerations for cell and gene therapy products, an fda perspective
-
36:56
fda’s clinical regulatory perspective: designing first-in-human trial for cellular and gene therapy
-
6:13
lymphoma: overview of chimeric antigen receptor (car) t cells
-
1:00:44
development advice for gene therapy products
-
1:20:20
chemistry, manufacturing controls (cmc) in an investigational new drug (ind) (7/14) redi 2017
-
1:32
car t cell therapy explained (animation) | city of hope
-
16:57
in vitro drug release testing for la drug products qc (16of35) complex generics - sep. 25-26, 2019
-
34:41
complex product characterization/analysis - session 2a
-
57:06
small molecules, biologics, and vaccines: three uniquely divergent roads to fda cmc approval
-
8:03:06
fda regulatory education for industry (redi) annual conference 2023 – biologics day 2
-
55:10
car-t cell therapy: now and in 2030 | laboratory medicine and pathology in individualized medicine
-
56:35
send for cber, what you need to know
-
16:19
referencing approved drug products in anda submissions (9of28) generic drugs forum – apr. 3-4, 2019
-
15:50
oncology center of excellence introduction and overview of the oncology therapy development workshop
-
5:21
regenerative medicine: fda regulatory process and clinical trials | conference preview
-
58:13
overcoming raw material challenges in cell and gene therapy manufacturing
-
59:19
understanding us fda regulatory responsibilities for cell therapy companies
-
7:31:34
fda regulatory education for industry (redi) – biologics track